Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is associated with a prothrombotic phenotype; however, the mechanisms responsible for enhanced platelet reactivity remain unclear. Proatherosclerotic lipid abnormalities are associated with both enhanced oxidant stress and the generation of biologically active oxidized lipids, including potential ligands for the scavenger receptor CD36, a major platelet glycoprotein. Using multiple mouse in vivo thrombosis models, we now demonstrate that genetic deletion of Cd36 protects mice from hyperlipidemia-associated enhanced platelet reactivity and the accompanying prothrombotic phenotype. Structurally defined oxidized choline glycerophospholipids that serve as high-affinity ligands for CD36 were at markedly increased levels in the plasma of hyperlipidemic mice and in the plasma of humans with low HDL levels, were able to bind platelets via CD36 and, at pathophysiological levels, promoted platelet activation via CD36. Thus, interactions of platelet CD36 with specific endogenous oxidized lipids play a crucial role in the well-known clinical associations between dyslipidemia, oxidant stress and a prothrombotic phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Platelet hyperreactivity and thrombosis risk are enhanced in the setting of numerous conditions associated with atherosclerotic heart disease, such as hyperlipidemia, oxidant stress, and hyperglycemia (Podrez et al., 2007; Chen et al., 2008; Zhu et al., 2012a).”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Podrez et al., 2007
Citations
Cites
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · cited 1×
“Because anti-inflammatory and antioxidant effects of HDL are well documente”
BackgroundFebbraio, M., Hajjar, D. P., & Silverstein, R. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14006 · Cited by 1,193 · cited 1×
“CD36 is implicated in a variety of pathological conditions, including atherosclerosis, diabetes and innate immunit”
BackgroundSelf-citationFebbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., Sharma, K., & Silverstein, R. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9259 · Cited by 1,044 · cited 1×
“Absence of CD36 in a mouse model of atherogenesis results in significant inhibition of atherosclerosi”
BackgroundSelf-citationCirculating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E
Huo, Y., Schober, A., Forlow, S. B., Smith, D. F., Hyman, M. C., Jung, S., Littman, D. R., Weber, C., & Ley, K. (2003) · Nature Medicine · doi:10.1038/nm810 · Cited by 1,005 · cited 1×
“Platelet P-selectin mediates the formation of platelet-monocyte aggregates, which have been implicated in several vascular disease processe”
BackgroundCD36 is a sensor of diacylglycerides
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zähringer, U., et al. (2005) · Nature · doi:10.1038/nature03253 · Cited by 873 · cited 1×
“To address any potential issues related to the mixed genetic background of the Cd36 −/− and Apoe −/− Cd36 −/− mice, we used independently generated, CD36-deficient 'oblivious' mic”
MethodWatson, A. D., Leitinger, N., Navab, M., Faull, K. F., Hörkkö, S., Witztum, J. L., Palinski, W., Schwenke, D., Salomon, R. G., Sha, W., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13597 · Cited by 753
Self-citationCD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism
André, P., Prasad, K. S. S., Denis, C. V., He, M., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 726
Platelet Function in Hyperlipoproteinemia
Carvalho, A. C. A., Colman, R. W., & Lees, R. S. (1974) · New England Journal of Medicine · doi:10.1056/nejm197402212900805 · Cited by 679
Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction
Trip, M. D., Cats, V. M., van Capelle, F. J. L., & Vreeken, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222201 · Cited by 617
Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro
Podrez, E. A., Schmitt, D., Hoff, H. F., & Hazen, S. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5549 · Cited by 492
Self-citation
Cited by
Items 301–400 of 513
CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function
Yang, M., & Silverstein, R. L. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000522 · Cited by 16
“[4] showing that CD36-linked hyperlipidemia and oxidative stress to a prothrombotic phenotype.”
BackgroundSelf-citationSchrör, K., Trenk, D., & Verheugt, F. W. A. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1758654 · Cited by 19
Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA
Wang, A., Xu, J., Chen, G., Wang, D., Johnston, S. C., Meng, X., Lin, J., Li, H., Cao, Y., Zhang, N., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006118 · Cited by 15
Halliday, S. J., Matthews, D. T., Talati, M. H., Austin, E. D., Su, Y. R., Absi, T., Fortune, N. L., Gailani, D., Matafonov, A., West, J. D., et al. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020906994 · Cited by 15
Circulating CD36 is increased in hyperlipidemic mice: Cellular sources and triggers of release
Biswas, S., Gao, D., Altemus, J. B., Rekhi, U., Chang, E., Febbraio, M., Byzova, T. V., & Podrez, E. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.004 · Cited by 17
Self-citationSubayyil, A. M. A., Basmaeil, Y. S., Alenzi, R., & Khatlani, T. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16848 · Cited by 15
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke
Zhang, N., Wang, Z., & Zhou, L. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.08.012 · Cited by 15
Eichinger, S., Kyrle, P. A., Kammer, M., Eischer, L., Kozma, M. O., & Binder, C. J. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13874 · Cited by 15
Seifert, J. M., von Eysmondt, H., Chatterjee, M., Gawaz, M., & Schäffer, T. E. (2021) · Cells · doi:10.3390/cells10112932 · Cited by 13
Huang, W., Li, R., Zhang, J., Chen, Y., Ramakrishnan, D. P., & Silverstein, R. L. (2022) · Translational research · doi:10.1016/j.trsl.2022.10.005 · Cited by 14
Self-citationOne immune cell to bind them all: platelet contribution to neurodegenerative disease
Moore, G. R., Melo-Escobar, I., Stegner, D., & Bracko, O. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00754-4 · Cited by 20
“CD36 interaction with oxLDL was shown to sensitize platelets to low doses of agonists [124] and participate in oxidative stress, hyperlipidemia, inflammation, and pathological thrombosis [125].”
BackgroundPrenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis
Banfi, C., Amadio, P., Zarà, M., Brioschi, M., Sandrini, L., & Barbieri, S. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052831 · Cited by 14
“Indeed, the accumulation of oxidized lipids in the plasma of high-risk patients is associated with increased platelet reactivity [15], whereas oxidized low-density lipoproteins (oxLDLs), both generated in vitro and isolated from subjects with cardiovascular disease (CVD), can contribute to platelet activation, suggest…”
BackgroundThe Role of Platelets in Diabetes Mellitus
Santilli, F., Simeone, P., & Liani, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00027-8 · Cited by 17
Platelet Acetyl-CoA Carboxylase Phosphorylation
Kautbally, S., Lepropre, S., Onselaer, M.-B., Lerigoleur, A., Ginion, A., de Meester, C., Ambroise, J., Boudjeltia, K. Z., Octave, M., Wéra, O., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.005 · Cited by 15
“PhosphoACC in response to oxLDL occurs downstream of CD36.”
BackgroundInfluentialChen, T., Li, L., Ye, B., Chen, W., Zheng, G., Xie, H., & Guo, Y. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12806 · Cited by 15
“These mechanisms may include endothelial dysfunction (26-28), foam cell formation (29-31), smooth muscle cell migration and proliferation (32,33), and the induction of platelet adhesion and aggregation (34,35).”
BackgroundGao, D., Willard, B. B., & Podrez, E. A. (2013) · Analytical Chemistry · doi:10.1021/ac4035949 · Cited by 16
Self-citationAn efficient synthesis of γ-hydroxy-α,β-unsaturated aldehydic esters of 2-lysophosphatidylcholine
Choi, J., Laird, J. M., & Salomon, R. G. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.058 · Cited by 14
Self-citationPCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP”
Silverstein, R. L. (2020) · Circulation · doi:10.1161/circulationaha.120.051940 · Cited by 14
Self-citationIs the suppression of CD36 a promising way for atherosclerosis therapy?
Wen, S., Zhi, X., Liu, H., Wang, X., Chen, Y., & Wang, L. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115965 · Cited by 15
Lee, B., Lin, K.-H., Hu, C., & Lo, S. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.04.006 · Cited by 13
Oxidized phospholipids are biomarkers, drug targets, and drug leads
Oskolkova, O., Birukova, A. A., Birukov, K. G., & Bochkov, V. N. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1043708 · Cited by 14
“, 2019) and stimulate chronic inflammation and deposition of lipids (Podrez et al., 2007; Bartolini Gritti and Binder, 2016).”
BackgroundThe involvement of CD36 in monocyte activation by antiphospholipid antibodies
Kato, M., Atsumi, T., Oku, K., Amengual, O., Nakagawa, H., Fujieda, Y., Otomo, K., Horita, T., Yasuda, S., & Koike, T. (2013) · Lupus · doi:10.1177/0961203313490242 · Cited by 13
Dong, A., Caicedo, J., Han, S. G., Mueller, P., Saha, S. P., Smyth, S. S., & Gairola, C. G. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.010 · Cited by 13
“Atherosclerosis and hyperlipidemia can increase platelet reactivity and propensity to thrombosis in mice(21;22).”
BackgroundNkambule, B. B., Davison, G. M., & Ipp, H. (2014) · Platelets · doi:10.3109/09537104.2014.909021 · Cited by 15
“Unlike CD62P, which is only released from the alpha granules and localizes on the surface of PLTs upon activation [46], PLT CD36 is expressed ubiquitously on the surface of PLTs [37].”
BackgroundIt's reticulated: the liver at the heart of atherosclerosis
Nagareddy, P. R., Noothi, S. K., Flynn, M., & Murphy, A. J. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0082 · Cited by 18
Collot-Teixeira, S., Delorenzo, F., & McGregor, J. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.154864 · Cited by 13
Arnoldussen, I. A. C., & Witkamp, R. F. (2021) · Biomolecules · doi:10.3390/biom11101455 · Cited by 14
“Additionally, dyslipidemia is associated with enhanced oxidant stress and synthesis of oxidized lipids, and specifically oxidized choline glycerophospholipids induce platelet aggregation via CD36 [37].”
BackgroundPanigrahi, S., Ghosh, S. K., Ferrari, B., Wyrick, J. M., Podrez, E. A., Weinberg, A., & Sieg, S. F. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.824954 · Cited by 12
“The pellet was re-suspended in 100 μL of HEPES-Tyrode’s buffer without calcium and GPP was prepared by passed through a Sepharose 2B column to remove any adhered plasma proteins from platelets as described elsewhere (Podrez et al., 2007; Panigrahi et al., 2013).”
MethodSelf-citationIntegrating Mechanisms in Thrombotic Peripheral Arterial Disease
Nagy, M., van der Meijden, P. E. J., Glunz, J., Schurgers, L. J., Lutgens, E., Cate, H. T., Heitmeier, S., & Spronk, H. M. H. (2022) · Pharmaceuticals · doi:10.3390/ph15111428 · Cited by 15
“I addition to TSP1, CD36 acts as the main platelet receptor for oxidized low-density lipoproteins (oxLDLs) [27,28], which are abundantly present in plaque areas.”
Cao, Z., Jiang, X., He, Y., & Zheng, X. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2401112 · Cited by 16
“OxLDL activates platelets by recognizing cluster of differentiation 36 (CD36) on platelets, and then, activated platelets exacerbate lipoprotein oxidation, further inducing thrombotic inflammation [95,96].”
BackgroundDuttaroy, A. K. (2024) · Nutrients · doi:10.3390/nu16213717 · Cited by 15
“Since platelet hyperreactivity increases in hyperlipidemia, hyperglycemia, oxidative stress, and cancers [42,43], Since platelet hyperreactivity increases in hyperlipidemia, hyperglycemia, oxidative stress, and cancers [42,43], understanding how platelets become hyperresponsive and contribute to…”
BackgroundBaranova, I. N., Bocharov, A. V., Vishnyakova, T. G., Chen, Z., Ke, Y., Birukova, A. A., Yuen, P. S. T., Tsuji, T., Star, R. A., Birukov, K. G., et al. (2024) · Cells · doi:10.3390/cells13231992 · Cited by 13
Karpouzas, G. A., Papotti, B., Ormseth, S. R., Palumbo, M., Hernández, E., Adorni, M. P., Zimetti, F., Budoff, M. J., & Ronda, N. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002411 · Cited by 12
Therapeutic Properties of Polyphenols Affect AMPK Molecular Pathway in HyperlipidemiaPreprint
Sotoudeheian, M., Hoseini, S., & Mirahmadi, S. (2023) · Preprints.org · doi:10.20944/preprints202301.0528.v1 · Cited by 16
Now in 3D! Novel insights into CD36 structure and function
May, S. C., & Sahoo, D. (2021) · Annals of Blood · doi:10.21037/aob-21-43 · Cited by 15
“In platelets, binding of CD36 to oxLDL and other dangerassociated molecular pattern structures promotes platelet activation and a pro-thrombotic state associated with chronic inflammatory disorders (16-18).”
BackgroundScavenger receptors: a key player in cardiovascular diseases
Ashraf, M. Z., & Sahu, A. (2012) · BioMolecular Concepts · doi:10.1515/bmc-2012-0003 · Cited by 12
“In hyperlipidemic CD36 -/- / ApoE -/- mice, the absence of CD36 signifi cantly protected these mice from the hyperlipidemia-related prothrombotic phenotype when compared to hyperlipidemic ApoE -/- without CD36 defi ciency (32) .”
BackgroundKessler, T., Schunkert, H., & von Hundelshausen, P. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714352 · Cited by 13
Oxidized lipids: not just another brick in the wall
Stamenković, A., Pierce, G. N., & Ravandi, A. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0490 · Cited by 14
“One of the members of this group known as KODA-PC can activate fibrinogen receptor on the platelets and induce expression of P-selectin that leads to formation of a platelet-monocyte aggregation (Podrez et al. 2007).”
BackgroundLipoprotein sialylation in atherosclerosis: Lessons from mice
Yu, L., Peng, J., & Mineo, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.953165 · Cited by 15
Role of oxidized phospholipids in cardiovascular pathology
Allen, D., Hasanally, D., & Ravandi, A. (2013) · Clinical Lipidology · doi:10.2217/clp.13.13 · Cited by 13
From damage signals to immune modulators: oxidized lipids in immunometabolic inflammation
Srivastava, N., & Wan, X. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.100990 · Cited by 14
“CD36 also binds to MDA and 4-HNE-modified proteins as well as 2-( ω -carboxyethyl) pyrrole adducts (40, 41).”
Targeting Cysteine Oxidation in Thrombotic Disorders
Yang, M., & Silverstein, R. L. (2024) · Antioxidants · doi:10.3390/antiox13010083 · Cited by 13
“…and include oxidative cysteine modi fi cation of Src family tyrosine kinases to enhance kinase activity and increase the activation of big MAP kinase ERK5 for a pro-aggregatory and pro-coagulant platelet phenotype. pathways within platelets, and the other is through downstream ROS signaling.”
BackgroundSelf-citationFeng, W., Valiyaveettil, M., Dudiki, T., Mahabeleshwar, G. H., André, P., Podrez, E. A., & Byzova, T. V. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0145-1 · Cited by 10
“WT or DiYF platelets were obtained and labeled with calcein green (Invitrogen, Carlsbad, CA), and then infused into the respective WT or DiYF mice (4-5 × 10(6) /g) via tail vein as previously described [20].”
MethodSelf-citationPlatelet Utilization: A Canadian Blood Services Research and Development Symposium
Webert, K. E., Alam, A. Q., CHARGÉ, S. B. P., & Sheffield, W. P. (2014) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2014.01.002 · Cited by 10
“Finally, in atherothrombosis, Dr Ni discussed new linkages uncovered in the last decade, for instance, between the platelet surface protein CD36, hyperlipidemia, and the emergence of a prothrombotic phenotype [65].”
BackgroundCarboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products
Salomon, R. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00304 · Cited by 10
Self-citationThe Role of Platelets in Atherothrombosis
Gawaz, M., & Borst, O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00026-6 · Cited by 10
Arriagada-Petersen, C., Fernández, P. C., Gomez, M., Ravello, N., Palomo, I. F., Eduardo Fuentes, Q., & Ávila, F. (2020) · Platelets · doi:10.1080/09537104.2020.1767770 · Cited by 10
“Interactions of platelet CD36 with specific endogenous oxidized lipids play a crucial role in the well-known clinical associations between dyslipidemia, oxidant stress and a prothrombotic phenotype [33,34].”
BackgroundLo, S., Lin, K., Hsieh, H.-H., Lin, D., & Hu, C. (2015) · Vox Sanguinis · doi:10.1111/vox.12356 · Cited by 10
The Vascular Function of Platelets
Watson, S. P., Morgan, N. V., & Harrison, P. (2015) · doi:10.1002/9781118853771.ch37 · Cited by 10
Conant, K. L., Marinelli, A., & Kaleeba, J. A. R. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00281 · Cited by 10
“CD36 is a class II glycoprotein involved in multiple physiological functions including cell adhesion, fatty acid uptake, non-opsonic phagocytosis, and angiogenesis (McGilvray et al., 2000; Podrez et al., 2007; Febbraio, 2007, 2009 ).”
BackgroundZhong, Y., Xie, Y., Lyu, J., Xie, Y., Zhao, C., & Yu, J. (2025) · Food Research International · doi:10.1016/j.foodres.2025.115759 · Cited by 9
Hyperactivity and Pro-inflammatory Functions of Platelets in Diabetes
Greaves, J., & Pula, G. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26190 · Cited by 15
Chen, H., Zhan, Y., Lou, Z., Mao, H. Z., Zhang, C., Li, X., Chen, G., Ouyang, H., Huang, Z., Wen, L., et al. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106448 · Cited by 10
Role of Phospholipases and Oxidized Phospholipids in Inflammation
Hasanally, D., Chaudhary, R., & Ravandi, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0464-8_3 · Cited by 9
“Due to increased polarity, OxPLs interact with membrane proteins resulting in binding to a wide variety of infl ammatory receptors [ 41 – 43 ].”
BackgroundZhang, M., & Jang, C. (2015) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2014.12.016 · Cited by 9
Tweaking the gain on platelet regulation: The tachykinin connection
Gibbins, J. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.010 · Cited by 9
Oxidized phospholipid-protein adducts: The future targets of interest
Ferreira, H. B., & Domingues, M. R. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109956 · Cited by 9
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 14
“11,73,85 Conversely, other studies contradicted these fi ndings, suggesting that Lp(a) might inhibit platelet activation by reducing collagen and ADP-induced platelet aggregation and impairing fi brinogen binding to GPIIb/IIIa.”
Chong, S., Mu, G., Cen, X., Xiang, Q., & Cui, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5381 · Cited by 8
“First, scavenger receptor cd36, a major platelet glycoprotein, plays a crucial role in dyslipidaemia and the prothrombotic phenotype (64).”
BackgroundResearch progress of nephrotic syndrome accompanied by thromboembolism
Tian, Y., Sun, B.-C., & Sun, G. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03474-8 · Cited by 13
“Oxidized LDL products enhance platelet activation and thrombogenesis [35].”
BackgroundRecently recognized platelet agonists
Morrell, C. N., & Maggirwar, S. B. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283497dfb · Cited by 10
Nielsen, T. B., Nielsen, M. H., & Handberg, A. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00037 · Cited by 8
“Studies have shown that when platelet CD36 binds oxLDL, specific intracellular signaling cascades are activated, resulting in platelet activation (9, 10), thus promoting a prothrombotic state and possibly the release of MVs.”
BackgroundConant, K. L., & Kaleeba, J. A. R. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00035 · Cited by 8
“PATHOGENESIS IN THE CO-INFECTED HOST CD36 is a class II glycoprotein involved in multiple physiological functions including cell adhesion, fatty acid uptake, non-opsonic phagocytosis, and angiogenesis (McGilvray et al., 2000; Podrez et al., 2007; Silverstein and Febbraio, 2007, 2009).”
Heemskerk, J. W. M., Cosemans, J. M. E. M., & van der Meijden, P. E. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_32 · Cited by 13
Mechanisms and consequences of myeloid adhesome dysfunction in atherogenesis
Zhevlakova, I., Liu, H., Dudiki, T., Gao, D., Yakubenko, V. P., Tkachenko, S., Cherepanova, O. A., Podrez, E. A., & Byzova, T. V. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae223 · Cited by 8
Self-citationThe NLRP3 inflammasome in platelets – form, functions, and future of the complex
Hindle, M. S., Berger, M., & Naseem, K. M. (2025) · Platelets · doi:10.1080/09537104.2025.2562267 · Cited by 8
Hitsumoto, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3031w · Cited by 7
“Oxidative stress causes the impairment of hemorheology through several mechanisms, such as platelet aggregation and increase in plasma viscosity [30, 31].”
BackgroundHitsumoto, T. (2017) · Cardiology Research · doi:10.14740/cr572w · Cited by 7
“Oxidative stress causes the impairment of hemorheology through several mechanisms, such as platelet aggregation and increased plasma viscosity [31, 32].”
BackgroundCD36: a promising therapeutic target in hematologic tumors
Yue, N., Jin, Q., Li, C., Zhang, L., Cao, J., & Wu, C. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2376178 · Cited by 9
“…in china confirmed that cD36 is expressed at low levels in reticulocytes and erythrocytes, and that cD36 meets the criteria to become a new blood grouping system [91]. in recent years, there has been accumulating evidence that cD36 has an important role in regulating platelet reactivity [92–94].”
Satti, H. H., Khaleel, E. F., Badi, R. M., Elrefaie, A. O., & Mostafa, D. G. (2020) · Platelets · doi:10.1080/09537104.2020.1756237 · Cited by 7
“This has been also demonstrated in HCCD animal models [15,42,43].”
ResultWang, H., Song, N., Li, J., Wang, Z., Ti, Y., Li, Y., Zhang, W., & Zhong, M. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15311 · Cited by 7
Silverstein, R. L. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303687 · Cited by 7
Self-citationMa, Y., Hu, J., Bi, X., Ma, J., Li, M., Li, R., Zhang, C., & Ya, F. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2024.11.016 · Cited by 6
Self-citationTan, J., Xu, W., Hu, S., Wang, J., Wang, L., Zhu, J. J., & Yang, Y. J. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39322 · Cited by 7
“Given the structure of oxidized phospholipid components and apolipoprotein(a), it is hypothesized that Lp(a) may facilitate platelet aggregation [15,16].”
Li, W., Wu, C., Zhou, X., Huang, X., Zhang, C., Ma, Y., Hu, J., Bi, X., Ma, J., Li, M., et al. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250165 · Cited by 6
Self-citationMechanisms Involved in Diabetes-Associated Platelet Hyperactivation
Randriamboavonjy, V. (2015) · InTech eBooks · doi:10.5772/60539 · Cited by 6
“Indeed, oxidized-LDL can directly interact with platelets specific receptors such as the lectinlike oxidized LDL receptor-1 [36] or the CD36 [37, 38].”
BackgroundThrombosis, Atherosclerosis and Atherothrombosis - New Insights and Experimental Protocols
Mijovski, M. B. (2015) · InTech eBooks · doi:10.5772/59831 · Cited by 7
Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs
Zhang, X., Gu, Y. H., Deng, H., Xu, Z. Q., Zhong, Z., Lyu, X. J., Jin, H. M., & Yang, X. H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.691336 · Cited by 6
Prothrombotic lipoprotein patterns in stroke
Podrez, E. A., & Byzova, T. V. (2016) · Blood · doi:10.1182/blood-2016-01-689034 · Cited by 6
“Among those are identifications of new interactions between platelet scavenger receptors and well-characterized products of phospholipid oxidation, which lead to platelet aggregation in hyperlipidemia.(4) However, the heterogeneity of plasma lipids combined with products of their oxidation is extremely high, therefore…”
BackgroundSelf-citationAspirin and lipoprotein(a) in primary prevention
Bhatia, H. S. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000891 · Cited by 7
Huang, L., Zhang, T., Zhu, Y., Lai, X., Tao, H., Xing, Y., & Li, Z. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s502314 · Cited by 5
Rodriguez, M., Dai, W., Lund, H., Osinski, K. I., Zhang, Z., Silverstein, R. L., & Zheng, Z. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101386 · Cited by 5
“High triglyceride levels associated with procoagulant factors II, VII, IX, X, XI, as well as endogenous thrombin potential and increased platelet activation [28-35].”
Self-citationDisabling the platelet’s brakes to promote thrombosis
Silverstein, R. L. (2015) · Blood · doi:10.1182/blood-2015-03-630822 · Cited by 5
Self-citationEffect of Glucose or Fat Challenge on Aspirin Resistance in Diabetes
Yassine, H. N., Davis‐Gorman, G., Stump, C. S., Thomson, S. S., Peterson, J., & McDonagh, P. F. (2010) · International Journal of Endocrinology · doi:10.1155/2010/820876 · Cited by 5
“Alternatively, oxidized LDL and oxidized choline glycerophospholipids induce platelet activation and thrombosis in fat fed mice through platelet CD36 [19].”
BackgroundGao, D., Sayre, L. M., & Podrez, E. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1441-8_3 · Cited by 5
Self-citationHitsumoto, T. (2017) · Diabetology International · doi:10.1007/s13340-017-0314-2 · Cited by 8
“Several mechanisms cause impairment of blood rheology via oxidative stress, such as platelet aggregation and elevation of plasma viscosity [31, 32].”
BackgroundPlatelets in the pathogenesis of vascular disease and their role as a therapeutic target
Prabhu, S., Sharma, R. P., & Peter, K. (2011) · University of Adelaide Press eBooks · doi:10.1017/upo9781922064004.012 · Cited by 5
Gain of function mechanisms triggering biological effects of oxidized phospholipids
Oskolkova, O., & Bochkov, V. N. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.08.002 · Cited by 5
Type 2 Diabetes Mellitus, Platelet Activation and Alzheimer's Disease: A Possible Connection.
Carbone, M. G., Pomara, N., Callegari, C., Marazziti, D., & Imbimbo, B. P. (2022) · PubMed · doi:10.36131/cnfioritieditore20220604 · Cited by 7
“Furthermore, oxidized-LDL can directly interact with platelets specific receptors such as the lectin-like oxidized LDL receptor-1 or the CD36 that amplify platelet activation (Carnevale et al., 2014; Chen et al., 2008; Chen et al., 2001; Podrez et al., 2007).”
BackgroundHitsumoto, T. (2017) · Cardiology Research · doi:10.14740/cr632w · Cited by 5
“In addition, several mechanisms are also reported that oxidative stress causes the impairment of hemorheology such as platelet aggregation and elevation of plasma viscosity [32, 33].”
BackgroundConceptualising research quality in medicine for evaluative bibliometrics
Andersen, J. P. (2013) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 11
Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients
Parvathaneni, K., Toress-Rodriguez, K., Meng, W., Knox, J. J., Xu, X., Weiskopf, D., Frey, N. V., Prak, E. T. L., Garfall, A. L., Betts, M. R., et al. (2021) · Blood · doi:10.1182/blood-2021-153730 · Cited by 5
Tsimikas, S., Kille, A., Kaier, K., Nührenberg, T. G., Franke, K., Valina, C. M., Yang, X., Leibundgut, G., Neumann, F., Westermann, D., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322347 · Cited by 5
Wang, N., Lan, C., Lu, H., Li, L., Liao, D., Xu, K., Sun, H., Tang, Y., Wang, Y., Mei, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285216 · Cited by 4
“…the platelet surface protein CD36 and oxidized low-density lipoprotein (oxLDL), which can promote platelet activation and contribute to thrombosis [42]. p38 MAPK is an ROS-sensitive signaling pathway, and an increase in ROS can promote endothelial cell apoptosis and activate inflammation, leading…”
BackgroundPI3KC2α inhibition is antithrombotic in blood from hypercholesterolemic mice
Setiabakti, N. M., Tarlac, V., Larsson, P., & Hamilton, J. R. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.030 · Cited by 6
Yan, M., Wang, Z., An, Y., Li, Z., Li, Y., Zhang, H., Li, C., Wang, L., Chen, L., Gao, C., et al. (2024) · Cell Biology International · doi:10.1002/cbin.12150 · Cited by 4
Managing Cardiovascular Complications in Diabetes
Betteridge, J. D., & Nicholls, S. J. (2014) · Wiley eBooks · doi:10.1002/9781118337967 · Cited by 6
Hitsumoto, T. (2018) · Cardiology Research · doi:10.14740/cr763w · Cited by 4
“Several mechanisms by which inflammation causes impairment of blood rheology have been proposed, including platelet aggregation and the elevation of plasma viscosity [27, 28].”
BackgroundTranslational Vascular Medicine: Pathogenesis, Diagnosis, and Treatment
Abraham, D., Handler, C., Dashwood, M. R., & Handler, C. (2011) · Springer eBooks · doi:10.1007/978-0-85729-920-8 · Cited by 7
Mechanisms of Platelet Activation in Diabetes Mellitus
Willecke, F., Nagareddy, P. R., & Murphy, A. J. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-66224-4_9 · Cited by 4
Metadata
- Authors
- Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., Chen, J., Zhang, R., Silverstein, R. L., & Hazen, S. L.
- Affiliations
- Cleveland Clinic (US)
- Case Western Reserve University (US)
- Versiti Blood Center of Wisconsin (US)
- Corresponding author
- Podrez, Eugene A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-08-26
- Volume
- 13
- Issue
- 9
- Pages
- 1086-1095
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC3042888
- OpenAlex
- W2029684068
- Cited by
- 513
- References
- 47
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 18 · 2023: 29 · 2022: 32 · 2021: 27 · 2020: 27 · 2019: 25 · 2018: 23 · 2017: 24 · 2016: 16 · 2015: 27 · 2014: 26 · 2013: 28 · 2012: 36
- FWCI
- 19.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL071625., P01HL046403, HL053315, HL 073311, HL076491, HL-072942, R01HL070083, P50 HL-81011, HL077107, HL077213, P01HL072942, P50HL077107, P01HL077107, R01HL077213, P01HL076491, HL 70621, HL70083, R01HL053315, HL-46403, P01HL073311, R01HL070621, P50HL081011, R01HL071625)
- National Center for Research Resources (M01RR018390)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- hyperlipidemia, oxidative stress, prothrombotic phenotype, oxidized lipids, platelet activation, scavenger receptors, dyslipidemia, thrombosis, HDL cholesterol
- MeSH terms
- Animals, Blood Platelets, Humans, Hyperlipidemias, Male, Phenotype, Phospholipids, Prothrombin, Thrombosis, Platelet Activation, Antigens, CD, Gene Deletion, Mice, Knockout, Oxidative Stress, CD36 Antigens, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.